Literature DB >> 28923864

Age-Related Trends in Adults with Community-Onset Bacteremia.

Ching-Chi Lee1,2,3,4, Jiun-Ling Wang3,5, Chung-Hsun Lee4,5, Yuan-Pin Hung3,5,6, Ming-Yuan Hong4,5, Chia-Ming Chang7,5, Wen-Chien Ko7,5.   

Abstract

To understand the epidemiological variation in bacteremia characteristics among differently aged populations, adults with community-onset bacteremia during a 6-year period were studied in a retrospective cohort. A total of 2,349 bacteremic patients were stratified into four age categories: young adults (18 to 44 years old; 196 patients; 8.3%), adults (45 to 64 years old; 707 patients; 30.1%), the elderly (65 to 84 years old; 1,098 patients; 46.7%), and the oldest old (≥85 years old; 348 patients; 14.8%). Age-related trends in critical illness (a Pitt bacteremia score of ≥4) at bacteremia onset, antibiotic-resistant pathogens (extended-spectrum β-lactamase [ESBL]-producing Escherichia coli, Klebsiella species, and Proteus mirabilis [EKP]; methicillin-resistant Staphylococcus aureus [MRSA]; and levofloxacin nonsusceptible EKP), inappropriate empirical antibiotic therapy (EAT), and 4-week mortality rate were observed. Using a multivariate regression model, critical illness at bacteremia onset (adjusted odds ratio [AOR], 9.03; P < 0.001) and inappropriate EAT (AOR, 2.67; P < 0.001) were the two leading predictors of 4-week mortality. Moreover, ESBL-producing EKP (AOR, 12.94; P < 0.001), MRSA (AOR, 8.66; P < 0.001), and levofloxacin-nonsusceptible EKP (AOR, 4.27; P < 0.001) were linked to inappropriate EAT. In conclusion, among adults with community onset bacteremia, significant positive age-related trends were noted in antibiotic-resistant pathogens and bacteremia severity, which were related to the increasing incidence of inappropriate EAT and 4-week mortality with age. Thus, different empirical antimicrobial regimens should be considered for distinct age groups.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  aging; appropriateness; bloodstream infections; community; empirical therapy

Mesh:

Substances:

Year:  2017        PMID: 28923864      PMCID: PMC5700340          DOI: 10.1128/AAC.01050-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  The atypical presentation of infection in old age.

Authors:  P Berman; D B Hogan; R A Fox
Journal:  Age Ageing       Date:  1987-07       Impact factor: 10.668

2.  The prevalence of methicillin-resistant staphylococcus aureus among the residents of six nursing homes for the elderly.

Authors:  N R O'Sullivan; C T Keane
Journal:  J Hosp Infect       Date:  2000-08       Impact factor: 3.926

3.  Epidemiology and prognosis of bacteremia: a 10-y study in a community hospital.

Authors:  M Javaloyas; D Garcia-Somoza; F Gudiol
Journal:  Scand J Infect Dis       Date:  2002

4.  Different impact of the appropriateness of empirical antibiotics for bacteremia among younger adults and the elderly in the ED.

Authors:  Ching-Chi Lee; Chia-Ming Chang; Ming-Yuan Hong; Hsiang-Chin Hsu; Wen-Chien Ko
Journal:  Am J Emerg Med       Date:  2012-09-20       Impact factor: 2.469

5.  Bloodstream infection: differences between young-old, old, and old-old patients.

Authors:  Gaetan Gavazzi; Marie-Reine Mallaret; Pascal Couturier; Anne Iffenecker; Alain Franco
Journal:  J Am Geriatr Soc       Date:  2002-10       Impact factor: 5.562

6.  Outcome of inadequate empirical antibiotic therapy in emergency department patients with community-onset bloodstream infections.

Authors:  Hang-Cheng Chen; Wen-Ling Lin; Chi-Chun Lin; Wen-Han Hsieh; Cheng-Hsien Hsieh; Meng-Huan Wu; Jiunn-Yih Wu; Chien-Chang Lee
Journal:  J Antimicrob Chemother       Date:  2012-12-21       Impact factor: 5.790

7.  Empirical third-generation cephalosporin therapy for adults with community-onset Enterobacteriaceae bacteraemia: Impact of revised CLSI breakpoints.

Authors:  Chih-Chia Hsieh; Chung-Hsun Lee; Ming-Chi Li; Ming-Yuan Hong; Chih-Hsien Chi; Ching-Chi Lee
Journal:  Int J Antimicrob Agents       Date:  2016-02-23       Impact factor: 5.283

8.  Comparison of clinical manifestations and outcome of community-acquired bloodstream infections among the oldest old, elderly, and adult patients.

Authors:  Chien-Chang Lee; Shey-Ying Chen; I-Jing Chang; Shyr-Chyr Chen; Shwu-Chong Wu
Journal:  Medicine (Baltimore)       Date:  2007-05       Impact factor: 1.889

9.  Comorbidity of chronic diseases in general practice.

Authors:  F G Schellevis; J van der Velden; E van de Lisdonk; J T van Eijk; C van Weel
Journal:  J Clin Epidemiol       Date:  1993-05       Impact factor: 6.437

10.  Epidemiology and outcome of nosocomial and community-onset bloodstream infection.

Authors:  D J Diekema; S E Beekmann; K C Chapin; K A Morel; E Munson; G V Doern
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

View more
  14 in total

1.  Appropriateness of empirical antibiotic prescription for bloodstream infections in an emergency department from 2006 to 2018: impact of the spread of ESBL-producing Enterobacterales.

Authors:  Marie Clemenceau; Samira Ahmed-Elie; Aurelie Vilfaillot; Richard Chocron; Fabrice Compain; David Lebeaux; Patrick Grohs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-09-22       Impact factor: 3.267

2.  Microorganism Distributions and Antimicrobial Susceptibility in Community-Onset Bacteremia: A 6-Year Longitudinal Multicenter Cohort in Southern Taiwan.

Authors:  Yi-Tzu Huang; Chao-Yung Yang; Chih-Chia Hsieh; Ming-Yuan Hong; Ching-Chi Lee
Journal:  J Acute Med       Date:  2022-03-01

3.  Microbial Distribution and Antibiotic Susceptibility of Lower Respiratory Tract Infections Patients From Pediatric Ward, Adult Respiratory Ward, and Respiratory Intensive Care Unit.

Authors:  Nan Duan; Jialin Du; Chenwei Huang; Haixia Li
Journal:  Front Microbiol       Date:  2020-06-30       Impact factor: 5.640

4.  The Pitt Bacteremia Score Predicts Mortality in Nonbacteremic Infections.

Authors:  Heather Henderson; Courtney L Luterbach; Eric Cober; Sandra S Richter; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Yohei Doi; Keith S Kaye; Scott Evans; Vance G Fowler; Robert A Bonomo; Anthony Harris; Sonia Napravnik; David Van Duin
Journal:  Clin Infect Dis       Date:  2020-04-15       Impact factor: 9.079

5.  Clinical characteristics and drug susceptibility patterns of Corynebacterium species in bacteremic patients with hematological disorders.

Authors:  Masahiro Abe; Muneyoshi Kimura; Hideyuki Maruyama; Tomohisa Watari; Sho Ogura; Shinsuke Takagi; Naoyuki Uchida; Yoshihito Otsuka; Shuichi Taniguchi; Hideki Araoka
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-04-24       Impact factor: 3.267

6.  Epidemiology of Community-Onset Staphylococcus aureus Bacteremia.

Authors:  James Y Yarovoy; Andrew A Monte; Bryan C Knepper; Heather L Young
Journal:  West J Emerg Med       Date:  2019-04-16

7.  Clinical Impact of Sequence Type 131 in Adults with Community-Onset Monomicrobial Escherichia Coli Bacteremia.

Authors:  Jiun-Ling Wang; Ching-Chi Lee; Chung-Hsun Lee; Nan-Yao Lee; Chih-Chia Hsieh; Yuan-Pin Hung; Hung-Jen Tang; Wen-Chien Ko
Journal:  J Clin Med       Date:  2018-12-03       Impact factor: 4.241

8.  Definitive Cefazolin Therapy for Stabilized Adults with Community-Onset Escherichia coli, Klebsiella Species, and Proteus mirabilis Bacteremia: MIC Matters.

Authors:  Chih-Chia Hsieh; Po-Lin Chen; Chung-Hsun Lee; Chao-Yung Yang; Ching-Chi Lee; Wen-Chien Ko
Journal:  J Clin Med       Date:  2020-01-07       Impact factor: 4.241

9.  Beneficial effects of early empirical administration of appropriate antimicrobials on survival and defervescence in adults with community-onset bacteremia.

Authors:  Ching-Chi Lee; Chung-Hsun Lee; Chao-Yung Yang; Chih-Chia Hsieh; Hung-Jen Tang; Wen-Chien Ko
Journal:  Crit Care       Date:  2019-11-20       Impact factor: 9.097

10.  Change in the Antimicrobial Resistance Profile of Extended-Spectrum β-Lactamase-Producing Escherichia coli.

Authors:  Motoyasu Miyazaki; Yota Yamada; Koichi Matsuo; Yukie Komiya; Masanobu Uchiyama; Nobuhiko Nagata; Tohru Takata; Shiro Jimi; Osamu Imakyure
Journal:  J Clin Med Res       Date:  2019-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.